Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
03 June 2020 | Story Rulanzen Martin | Photo Rulanzen Martin
Prof Kobus Marais, the founder of the JTSA, at the launch of his Indexicality Research Forum in 2019.
The newly launched Journal for Translation Studies in Africa (JTSA) by Prof Kobus Marais from the Department of Linguistics and Language Practice at the University of the Free State (UFS), is the result of various efforts over a period of more than a decade.

“The first Summer School for Translation Studies in Africa 2009 stands out as one of the first efforts to think about the concept of translation in Africa,” said Prof Marais. A subsequent series of summer schools also led to the formation of the Association for Translation Studies (ATSA) in Africa in 2016 in Nairobi, Kenya. 

The journal is an open-sourced, peer-reviewed publication, boasting scholarly papers, book reviews, opinion pieces and work by young scholars within translation studies. The first edition of the journal was made possible with financial support from Prof Corli Witthuhn, Vice-Rector: Research, Innovation and Internationalisation and the Directorate: Research Development at the UFS. 


First edition to focus on African translation phenomena 

The JTSA is an attempt to start scholarly debate with a focus on Africa as a developmental context in which to study translation phenomena and practices. The first edition will guest edited by Dr Carmen Delgado Luchner from the University of Geneva who is an accredited European Union interpreter. In the editorial of the first edition, Prof Marais and Dr Delgado Luchner set out the vision of the journal, namely: “to offer a high-level publication outlet to translation-studies scholars from Africa, African translation-studies scholars in the diaspora and scholars in general working on African topics in translation studies”.

“It would disseminate their work in order to advance the field of translation studies in Africa and to position Africa in relation to the rest of the world as far as translation studies are concerned.”

The editorial board of the JTSA consists of Prof Kobus Marais, the editor-in-chief, who will be assisted by three sub-editors, who each take responsibility for one of the sections. They are: Dr Francis Ajayi – Agenda (opinion pieces); Dr Felix Awung – reviews; and Dr Mwamba Chibamba – New Voices (young scholars). 

Apart from the editorial board there is an International Advisory Board consisting of various translation scholars. “This journal will be devoted to translation studies in Africa, with its wealth of languages, its innovative and creative language and translation practices and policies,” said Prof Reine Meylaerts, Vice-Rector: Research Policy at Katholieke Universitiet Leuven, who serves on the advisory board. She also praised the JTSA for its multilingualism and being an example of Open Science. 

Other scholars on the advisory board are: Prof Rita Kothari (Ashoka University in India); Prof John Milton (University of São Paulo, Brazil); Prof Jacobus Naude (UFS); Prof Maria Tymoczko (University of Massachusetts, Amherst); and Prof Rita Wilson (Monash University). 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept